Drawing for LIPIGEN

USPTO serial 77384324

LIPIGEN

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CHARLON, BARNEY
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LIPIGEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Steven N. Terranova, Esq.

STEVEN N. TERRANOVA, ESQ. WITHROW & TERRANOVA, PLLC100 REGENCY FOREST DR STE 160CARY, NC 27518-8598UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Ophthalmic preparations, eye drops, and medicated eye gels and medicated gels applied to the meibomian glands used for the treatment of ocular disorders, namely, dry eye and meibomian gland dysfunctionACTIVE—
009Computer hardware and software, and parts and accessories therefor, for use with apparatus for analyzing, diagnosing, treating, and monitoring eye disease, namely, dry eye and meibomian gland dysfunctionACTIVE—
010Medical apparatuses and devices, and parts and accessories therefor, used for analyzing, diagnosing, treating, and monitoring eye disease, namely, dry eye and meibomian gland dysfunction; Medical devices, and parts and accessories therefor, for expressing obstructions or occlusions from meibomian glands; Medical heater used primarily for medical purposes, namely, for applying heat to a patient's eye and related eye structure for treating eye diseases, namely, dry eye and meibomian gland dysfunction; Medical devices, namely, medical contact lens used primarily for medical purposes containing an electrical heating element for applying heat to meibomian glands when installed on a patient's eye for treating dry eye and meibomian gland dysfunction; Optical and photographic apparatus and instruments, and parts and accessories therefor, namely, interferometers and cameras, for analyzing, diagnosing, and monitoring eye disease, namely, dry eye and meibomian gland dysfunction; medical imaging apparatuses and devices comprising optical lens, camera, lamp, LED, spectrometer, used for analyzing, diagnosing, and monitoring eye disease, namely, dry eye and meibomian gland dysfunction; electronic medical temperature controller, and parts and accessories therefor, used primarily for temperature controller purposes, namely, for delivering and controlling heat to meibomian glands for use in treating eye disease, namely, dry eye and meibomian gland dysfunction; electronic medical pressure controller, and parts and accessories therefor, used primarily for controlling pressure, namely, for applying and controlling pressure to the meibomian glands for use in treating eye disease, namely, dry eye and meibomian gland dysfunction; electronic medical fluid transfer controller, and parts and accessories therefor, used primarily for controlling and transferring heated fluid to the eye for use in treating eye disease, namely, dry eye and meibomian gland dysfunctionACTIVE—
016Printed instructional, educational and teaching materials in the field of eye disease, namely, dry eye and meibomian gland dysfunction; Printed instructional, educational and teaching materials for analysis, diagnosis, treatment, and monitoring of eye disease, namely, dry eye and meibomian gland dysfunctionACTIVE—
041Education services, namely, classes, conferences, seminars, workshops, in the field of eye disease, namely, dry eye and meibomian gland dysfunction; Education services, namely, providing seminars, tutorials, workshops for analyzing, diagnosing, treating, and monitoring eye disease, namely, dry eye and meibomian gland dysfunction; Training services in the field of eye disease, namely, dry eye and meibomian gland dysfunction; Training services, namely, providing seminars, tutorials, workshops for analyzing, diagnosing, treating, and monitoring eye disease, namely,dry eye and meibomian gland dysfunctionACTIVE—
044Medical services, namely, providing medical analysis, diagnosis, treatment, and monitoring of eye diseases and conditions; Medical services, namely, providing medical analysis, diagnosis, treatment, and monitoring of dry eye and meibomian gland dysfunction; Providing medical information related to eye disease, namely, dry eye and meibomian gland dysfunction, for educational purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 6, 2009MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 6, 2009ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 15, 2009DOCKASSIGNED TO EXAMINER—
Jan 14, 2009ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Dec 2, 2008NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 9, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 20, 2008NPUBNOTICE OF PUBLICATION—
Aug 8, 2008CNEAEXAMINERS AMENDMENT MAILED—
Aug 7, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 7, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 7, 2008XAECEXAMINER'S AMENDMENT ENTERED—
Aug 7, 2008CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 4, 2008ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Aug 1, 2008PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Jul 21, 2008CNEAEXAMINERS AMENDMENT MAILED—
Jul 18, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 18, 2008ALIEASSIGNED TO LIE—
Jul 18, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 18, 2008XAECEXAMINER'S AMENDMENT ENTERED—
Jul 18, 2008CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 1, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 1, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 1, 2008TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 12, 2008CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 9, 2008CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 8, 2008DOCKASSIGNED TO EXAMINER—
Feb 4, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance